<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01986062</url>
  </required_header>
  <id_info>
    <org_study_id>AR11.001</org_study_id>
    <nct_id>NCT01986062</nct_id>
  </id_info>
  <brief_title>Crossover Study to Evaluate the Efficacy of AR11 in Pediatric Patients With ADHD in a Laboratory Classroom Setting</brief_title>
  <official_title>A Multicenter, Dose-Optimized, Double-Blind, Randomized, Placebo-Controlled, Crossover Study to Evaluate the Efficacy of AR11 (Amphetamine Sulfate) in Pediatric Patients (Ages 6-12) With Attention Deficit Hyperactivity Disorder (ADHD) in a Laboratory Classroom</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arbor Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arbor Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a dose-optimized, randomized, double-blind, placebo-controlled crossover study in
      approximately 100 pediatric patients (aged 6 to 12 years) with ADHD. Eligible patients will
      enroll in the study to take open-label AR11 twice daily and undergo dose optimization
      activities for 8 weeks. Patients who achieve a stable dose during the dose optimization
      period will continue participation and will be randomized to take double-blind medication
      (AR11 or placebo) orally twice daily for 1 week. At the end of the first double-blind
      treatment period, patients will be evaluated for ADHD symptoms in a laboratory classroom
      setting utilizing SKAMP and PERMP assessments. At the end of the second double blind
      treatment period, patients will be evaluated for ADHD symptoms in a second laboratory
      classroom setting utilizing SKAMP and PERMP assessments.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SKAMP-Combined Scores</measure>
    <time_frame>2 hours post-dose</time_frame>
    <description>Swanson, Kotkin, Agler, M-Flynn, and Pelham Scale [SKAMP]-combined scores measured during Laboratory Classroom Days. The SKAMP scale is a validated subjective measure of ADHD symptoms in a laboratory classroom, comprised of 13 items on which subjects are rated according to a 7 point scale (0=normal to 6=maximal impairment); maximum score 78. The SKAMP-combined score is obtained by summing the rating values for each of the 13 items, whereby the higher the SKAMP score, the greater the impairment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SKAMP-Combined Scores</measure>
    <time_frame>0.75, 4, 6, 8, 10 hours post-dose</time_frame>
    <description>Swanson, Kotkin, Agler, M-Flynn, and Pelham Scale [SKAMP]-combined scores measured during Laboratory Classroom Days. The SKAMP scale is a validated subjective measure of ADHD symptoms in a laboratory classroom, comprised of 13 items on which subjects are rated according to a 7 point scale (0=normal to 6=maximal impairment); maximum score 78. The SKAMP-combined score is obtained by summing the rating values for each of the 13 items, whereby the higher the SKAMP score, the greater the impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SKAMP Subscale - Attention Scores</measure>
    <time_frame>0.75, 2, 4, 6, 8, and 10 hours post-dose</time_frame>
    <description>The SKAMP scale is a validated subjective measure of ADHD symptoms. It is comprised of 13 items (grouped under the subcategories of attention, deportment, quality of work, and compliance) on which subjects are rated according to a 7-point scale (0 = normal to 6 = maximal impairment). The SKAMP-Attention subscale score is comprised of four of the 13 items with a maximum score of 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SKAMP Subscale - Deportment Scores</measure>
    <time_frame>0.75, 2, 4, 6, 8, and 10 hours post-dose</time_frame>
    <description>The SKAMP scale is a validated subjective measure of ADHD symptoms. It is comprised of 13 items (grouped under the subcategories of attention, deportment, quality of work, and compliance) on which subjects are rated according to a 7-point scale (0 = normal to 6 = maximal impairment). The SKAMP-Deportment subscale score is comprised of four of the 13 items with a maximum score of 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PERM-P Scores - Number of Problems Attempted</measure>
    <time_frame>0.75, 2, 4, 6, 8, and 10 hours post-dose</time_frame>
    <description>Permanent Product Measure of Performance (PERMP) assessments measured during Laboratory Classroom Days. The PERMP is an individualized, five-page math exam consisting of 400 problems. Subjects are instructed to complete as many math problems as possible in 10 minutes. Performance is evaluated using the number of problems attempted (maximum score = 400) and the number of problems correct (maximum score = 400).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PERM-P Scores - Number of Problems Correct</measure>
    <time_frame>0.75, 2, 4, 6, 8, and 10 hours post-dose</time_frame>
    <description>Permanent Product Measure of Performance (PERMP) assessments measured during Laboratory Classroom Days. The PERMP is an individualized, five-page math exam consisting of 400 problems. Subjects are instructed to complete as many math problems as possible in 10 minutes. Performance is evaluated using the number of problems attempted (maximum score = 400) and the number of problems correct (maximum score = 400).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">97</enrollment>
  <condition>Attention Deficit Hyperactivity Disorder (ADHD)</condition>
  <arm_group>
    <arm_group_label>AR11 (amphetamine sulfate) (1 week) - double blind</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AR11, administered orally, BID, for one week (crossover to placebo administration week 2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (1 week) - double blind</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, administered orally, BID, for one week (crossover to AR11 administration week 2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AR11</intervention_name>
    <arm_group_label>AR11 (amphetamine sulfate) (1 week) - double blind</arm_group_label>
    <other_name>amphetamine sulfate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo (1 week) - double blind</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female between 6 and 12 years of age, inclusive, at the time of Screening.

          2. Diagnosed as meeting Diagnostic and Statistical Manual of Mental Disorders, Fourth
             Edition, Text Revision (DSM-IV-TR) criteria for ADHD.

          3. A clinician-administered Clinical Global Impression of Severity (CGI-S) score of 3 or
             greater.

          4. An ADHD Rating Scale (ADHD-RS) score at Screening and Baseline greater than or equal
             to the 90th percentile normative values for gender and age in at least one of the
             following categories: hyperactive-impulsive subscale, inattentive subscale, or total
             score.

        Exclusion Criteria:

          1. Secondary or co-morbid diagnoses other than ADHD, with the exception of simple
             phobias, oppositional defiant disorder, elimination disorders, motor skills disorders,
             communication disorders, learning disorders, adjustment disorders, and sleep disorders
             if, in the opinion of the investigator, the associated symptoms do not confound
             assessment of safety or efficacy.

          2. Clinically significant cognitive impairment as assessed in the clinical judgment of
             the Investigator.

          3. History of any of the following medical disorders: seizure disorder (excluding a
             history of febrile seizures), structural cardiac disorders, serious cardiac
             conditions, hypertension, untreated thyroid disease, glaucoma, Tourette's disorder, or
             chronic tics.

          4. Clinically significant abnormal ECG finding or abnormal cardiac finding on physical
             exam (including presence of a pathologic murmur) at Screening.

          5. Use of any psychotropic medication (sedative hypnotics prescribed as a sleep aid at a
             stable dose for at least 30 days prior to Baseline, at bedtime only, are allowed
             during the study).

          6. A history of hypersensitivity or intolerance to any formulation of amphetamine or
             lisdexamfetamine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurence Downey, MD</last_name>
    <role>Study Director</role>
    <affiliation>Arbor Pharmaceuticals, LLC.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Florida Clinical Research Center, LLC.</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Clinical Research Center, LLC</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Research Associates</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Psychiatry and Behavioral Medicine, Inc.</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bayou City Research Ltd.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westex Clinical Investigations</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>79423</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Childress AC, Brams M, Cutler AJ, Kollins SH, Northcutt J, Padilla A, Turnbow JM. The Efficacy and Safety of Evekeo, Racemic Amphetamine Sulfate, for Treatment of Attention-Deficit/Hyperactivity Disorder Symptoms: A Multicenter, Dose-Optimized, Double-Blind, Randomized, Placebo-Controlled Crossover Laboratory Classroom Study. J Child Adolesc Psychopharmacol. 2015 Jun;25(5):402-14. doi: 10.1089/cap.2014.0176. Epub 2015 Feb 18.</citation>
    <PMID>25692608</PMID>
  </reference>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 11, 2013</study_first_submitted>
  <study_first_submitted_qc>November 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2013</study_first_posted>
  <results_first_submitted>June 5, 2015</results_first_submitted>
  <results_first_submitted_qc>March 18, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 19, 2016</results_first_posted>
  <last_update_submitted>March 18, 2016</last_update_submitted>
  <last_update_submitted_qc>March 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ADHD</keyword>
  <keyword>AR11</keyword>
  <keyword>classroom design</keyword>
  <keyword>amphetamine sulfate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
    <mesh_term>Hyperkinesis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amphetamine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>AR11 (1 Week) Then Placebo (1 Week) - Double Blind</title>
          <description>AR11, administered orally, BID, for one week (crossover to placebo administration week 2)</description>
        </group>
        <group group_id="P2">
          <title>Placebo (1 Week) Then AR11 (1 Week) - Double Blind</title>
          <description>Placebo, administered orally, BID, for one week (crossover to AR11administration week 2)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AR11 (1 Week) Then Placebo (1 Week) - Double Blind</title>
          <description>AR11, administered orally, BID for one week (crossover to placebo administration week 2)</description>
        </group>
        <group group_id="B2">
          <title>Placebo (1 Week) Then AR11 (1 Week) - Double Blind</title>
          <description>Placebo, administered orally, BID for one week (crossover to AR11 administration week 2)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="47"/>
            <count group_id="B2" value="50"/>
            <count group_id="B3" value="97"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.6" spread="1.97"/>
                    <measurement group_id="B2" value="9.6" spread="1.78"/>
                    <measurement group_id="B3" value="9.6" spread="1.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>SKAMP-Combined Scores</title>
        <description>Swanson, Kotkin, Agler, M-Flynn, and Pelham Scale [SKAMP]-combined scores measured during Laboratory Classroom Days. The SKAMP scale is a validated subjective measure of ADHD symptoms in a laboratory classroom, comprised of 13 items on which subjects are rated according to a 7 point scale (0=normal to 6=maximal impairment); maximum score 78. The SKAMP-combined score is obtained by summing the rating values for each of the 13 items, whereby the higher the SKAMP score, the greater the impairment.</description>
        <time_frame>2 hours post-dose</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>AR11 (Amphetamine Sulfate)</title>
            <description>AR11, administered orally, BID, 10-40 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, administered orally, BID</description>
          </group>
        </group_list>
        <measure>
          <title>SKAMP-Combined Scores</title>
          <description>Swanson, Kotkin, Agler, M-Flynn, and Pelham Scale [SKAMP]-combined scores measured during Laboratory Classroom Days. The SKAMP scale is a validated subjective measure of ADHD symptoms in a laboratory classroom, comprised of 13 items on which subjects are rated according to a 7 point scale (0=normal to 6=maximal impairment); maximum score 78. The SKAMP-combined score is obtained by summing the rating values for each of the 13 items, whereby the higher the SKAMP score, the greater the impairment.</description>
          <population>ITT Population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" spread="8.24"/>
                    <measurement group_id="O2" value="17.8" spread="1.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SKAMP-Combined Scores</title>
        <description>Swanson, Kotkin, Agler, M-Flynn, and Pelham Scale [SKAMP]-combined scores measured during Laboratory Classroom Days. The SKAMP scale is a validated subjective measure of ADHD symptoms in a laboratory classroom, comprised of 13 items on which subjects are rated according to a 7 point scale (0=normal to 6=maximal impairment); maximum score 78. The SKAMP-combined score is obtained by summing the rating values for each of the 13 items, whereby the higher the SKAMP score, the greater the impairment.</description>
        <time_frame>0.75, 4, 6, 8, 10 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AR11 (Amphetamine Sulfate)</title>
            <description>AR11, administered orally, BID, 10-40 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, administered orally, BID</description>
          </group>
        </group_list>
        <measure>
          <title>SKAMP-Combined Scores</title>
          <description>Swanson, Kotkin, Agler, M-Flynn, and Pelham Scale [SKAMP]-combined scores measured during Laboratory Classroom Days. The SKAMP scale is a validated subjective measure of ADHD symptoms in a laboratory classroom, comprised of 13 items on which subjects are rated according to a 7 point scale (0=normal to 6=maximal impairment); maximum score 78. The SKAMP-combined score is obtained by summing the rating values for each of the 13 items, whereby the higher the SKAMP score, the greater the impairment.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0.75 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8" spread="10.56"/>
                    <measurement group_id="O2" value="17.3" spread="11.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6" spread="10.04"/>
                    <measurement group_id="O2" value="19.8" spread="11.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.5" spread="10.38"/>
                    <measurement group_id="O2" value="20.2" spread="11.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0" spread="11.76"/>
                    <measurement group_id="O2" value="22.0" spread="12.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.5" spread="11.08"/>
                    <measurement group_id="O2" value="20.8" spread="13.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SKAMP Subscale - Attention Scores</title>
        <description>The SKAMP scale is a validated subjective measure of ADHD symptoms. It is comprised of 13 items (grouped under the subcategories of attention, deportment, quality of work, and compliance) on which subjects are rated according to a 7-point scale (0 = normal to 6 = maximal impairment). The SKAMP-Attention subscale score is comprised of four of the 13 items with a maximum score of 24.</description>
        <time_frame>0.75, 2, 4, 6, 8, and 10 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AR11 (Amphetamine Sulfate)</title>
            <description>AR11, administered orally, BID, 10-40 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, administered orally, BID</description>
          </group>
        </group_list>
        <measure>
          <title>SKAMP Subscale - Attention Scores</title>
          <description>The SKAMP scale is a validated subjective measure of ADHD symptoms. It is comprised of 13 items (grouped under the subcategories of attention, deportment, quality of work, and compliance) on which subjects are rated according to a 7-point scale (0 = normal to 6 = maximal impairment). The SKAMP-Attention subscale score is comprised of four of the 13 items with a maximum score of 24.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0.75 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="2.64"/>
                    <measurement group_id="O2" value="3.4" spread="3.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2.0 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="2.26"/>
                    <measurement group_id="O2" value="3.4" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4.0 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="2.68"/>
                    <measurement group_id="O2" value="4.0" spread="3.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6.0 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="2.43"/>
                    <measurement group_id="O2" value="3.6" spread="2.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8.0 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="2.8"/>
                    <measurement group_id="O2" value="4.1" spread="3.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10.0 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="3.15"/>
                    <measurement group_id="O2" value="4.0" spread="3.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SKAMP Subscale - Deportment Scores</title>
        <description>The SKAMP scale is a validated subjective measure of ADHD symptoms. It is comprised of 13 items (grouped under the subcategories of attention, deportment, quality of work, and compliance) on which subjects are rated according to a 7-point scale (0 = normal to 6 = maximal impairment). The SKAMP-Deportment subscale score is comprised of four of the 13 items with a maximum score of 24.</description>
        <time_frame>0.75, 2, 4, 6, 8, and 10 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AR11 (Amphetamine Sulfate)</title>
            <description>AR11, administered orally, BID, 10-40 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, administered orally, BID</description>
          </group>
        </group_list>
        <measure>
          <title>SKAMP Subscale - Deportment Scores</title>
          <description>The SKAMP scale is a validated subjective measure of ADHD symptoms. It is comprised of 13 items (grouped under the subcategories of attention, deportment, quality of work, and compliance) on which subjects are rated according to a 7-point scale (0 = normal to 6 = maximal impairment). The SKAMP-Deportment subscale score is comprised of four of the 13 items with a maximum score of 24.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0.75 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="3.53"/>
                    <measurement group_id="O2" value="3.9" spread="4.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2.0 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="2.79"/>
                    <measurement group_id="O2" value="4.0" spread="4.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4.0 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="3.47"/>
                    <measurement group_id="O2" value="4.7" spread="4.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6.0 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="4.21"/>
                    <measurement group_id="O2" value="4.3" spread="4.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8.0 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="4.38"/>
                    <measurement group_id="O2" value="4.9" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10.0 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="3.72"/>
                    <measurement group_id="O2" value="4.9" spread="5.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PERM-P Scores - Number of Problems Attempted</title>
        <description>Permanent Product Measure of Performance (PERMP) assessments measured during Laboratory Classroom Days. The PERMP is an individualized, five-page math exam consisting of 400 problems. Subjects are instructed to complete as many math problems as possible in 10 minutes. Performance is evaluated using the number of problems attempted (maximum score = 400) and the number of problems correct (maximum score = 400).</description>
        <time_frame>0.75, 2, 4, 6, 8, and 10 hours post-dose</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>AR11 (Amphetamine Sulfate)</title>
            <description>AR11, administered orally, BID, 10-40 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, administered orally, BID</description>
          </group>
        </group_list>
        <measure>
          <title>PERM-P Scores - Number of Problems Attempted</title>
          <description>Permanent Product Measure of Performance (PERMP) assessments measured during Laboratory Classroom Days. The PERMP is an individualized, five-page math exam consisting of 400 problems. Subjects are instructed to complete as many math problems as possible in 10 minutes. Performance is evaluated using the number of problems attempted (maximum score = 400) and the number of problems correct (maximum score = 400).</description>
          <population>ITT</population>
          <units>number of problems attempted</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0.75 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111.6" spread="53.53"/>
                    <measurement group_id="O2" value="91.2" spread="47.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2.0 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113.4" spread="51.27"/>
                    <measurement group_id="O2" value="85.7" spread="46.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4.0 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113.2" spread="56.28"/>
                    <measurement group_id="O2" value="85.1" spread="45.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6.0 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101.3" spread="54.26"/>
                    <measurement group_id="O2" value="74.9" spread="43.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8.0 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.2" spread="56.11"/>
                    <measurement group_id="O2" value="76.4" spread="47.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10.0 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.2" spread="55.53"/>
                    <measurement group_id="O2" value="76.3" spread="45.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PERM-P Scores - Number of Problems Correct</title>
        <description>Permanent Product Measure of Performance (PERMP) assessments measured during Laboratory Classroom Days. The PERMP is an individualized, five-page math exam consisting of 400 problems. Subjects are instructed to complete as many math problems as possible in 10 minutes. Performance is evaluated using the number of problems attempted (maximum score = 400) and the number of problems correct (maximum score = 400).</description>
        <time_frame>0.75, 2, 4, 6, 8, and 10 hours post-dose</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>AR11 (Amphetamine Sulfate)</title>
            <description>AR11, administered orally, BID, 10-40 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, administered orally, BID</description>
          </group>
        </group_list>
        <measure>
          <title>PERM-P Scores - Number of Problems Correct</title>
          <description>Permanent Product Measure of Performance (PERMP) assessments measured during Laboratory Classroom Days. The PERMP is an individualized, five-page math exam consisting of 400 problems. Subjects are instructed to complete as many math problems as possible in 10 minutes. Performance is evaluated using the number of problems attempted (maximum score = 400) and the number of problems correct (maximum score = 400).</description>
          <population>ITT</population>
          <units>number of problems correct</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0.75 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104.5" spread="54.49"/>
                    <measurement group_id="O2" value="83.9" spread="46.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2.0 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107.1" spread="53.15"/>
                    <measurement group_id="O2" value="78.9" spread="44.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4.0 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107.0" spread="57.46"/>
                    <measurement group_id="O2" value="79.9" spread="45.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6.0 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.6" spread="55.43"/>
                    <measurement group_id="O2" value="70.5" spread="43.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8.0 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.7" spread="57.28"/>
                    <measurement group_id="O2" value="71.5" spread="47.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10.0 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.9" spread="55.29"/>
                    <measurement group_id="O2" value="72.3" spread="45.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AE reporting occurred during the 8-week open label treatment phase (i.e. AR11 dose optimization) and the 2-week double blind phase (i.e. crossover period)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>AR11</title>
          <description>AR11, administered orally, BID for one week</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo, administered orally, BID for one week</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper abdominal pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="97"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Decreased weight</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="97"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="97"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Mood swings</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Steve Caras</name_or_title>
      <organization>Arbor Pharmaceuticals</organization>
      <phone>(470) 235-2327</phone>
      <email>scaras@arborpharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

